Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist

被引:48
作者
Lochard, N
Thibault, G
Silversides, DW
Touyz, RM
Reudelhuber, TL
机构
[1] Inst Rech Clin Montreal, Lab Mol Biochem Hypertens, Montreal, PQ H2W 1R7, Canada
[2] Inst Rech Clin Montreal, Lab Cell Biol Hypertens, Montreal, PQ H2W 1R7, Canada
[3] Inst Rech Clin Montreal, Lab Expt Hypertens, Montreal, PQ H2W 1R7, Canada
[4] Univ Montreal, Fac Med Vet, Ctr Rech Reprod Anim, St Hyacinthe, PQ J2S 7C6, Canada
关键词
angiotensin IV; transgenic model; hypertension; brain renin-angiotensin system;
D O I
10.1161/01.RES.0000130654.56599.40
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Angiotensin IV (Ang IV) is a metabolite of the potent vasoconstrictor angiotensin II (Ang II). Because specific binding sites for this peptide have been reported in numerous tissues including the brain, it has been suggested that a specific Ang IV receptor (AT4) might exist. Bolus injection of Ang IV in brain ventricles has been implicated in learning, memory, and localized vasodilatation. However, the functions of Ang IV in a physiological context are still unknown. In this study, we generated a transgenic (TG) mouse model that chronically releases Ang IV peptide specifically in the brain. TG mice were found to be hypertensive by the tail-cuff method as compared with control littermates. Treatment with the angiotensin-converting enzyme inhibitor captopril had no effect on blood pressure, but surprisingly treatment with the Ang II AT1 receptor antagonist candesartan normalized the blood pressure despite the fact that the levels of Ang IV in the brains of TG mice were only 4-fold elevated over the normal endogenous level of Ang peptides. Calcium mobilization assays performed on cultured CHO cells chronically transfected with the AT1 receptor confirm that low-dose Ang IV can mobilize calcium via the AT1 receptor only in the presence of Ang II, consistent with an allosteric mechanism. These results suggest that chronic elevation of Ang IV in the brain can induce hypertension that can be treated with angiotensin II AT1 receptor antagonists.
引用
收藏
页码:1451 / 1457
页数:7
相关论文
共 39 条
[1]   Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase [J].
Albiston, AL ;
McDowall, SG ;
Matsacos, D ;
Sim, P ;
Clune, E ;
Mustafa, T ;
Lee, J ;
Mendelsohn, FAO ;
Simpson, RJ ;
Connolly, LM ;
Chai, SY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :48623-48626
[2]  
[Anonymous], 1988, Antibodies: A Laboratory Manual
[3]   Tissue renin-angiotensin systems:: new insights from experimental animal models in hypertension research [J].
Bader, J ;
Peters, J ;
Baltatu, O ;
Müller, DN ;
Luft, FC ;
Ganten, D .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (2-3) :76-102
[4]  
BENNETT JP, 1976, J BIOL CHEM, V251, P7423
[5]   BEHAVIORAL-EFFECTS OF ANGIOTENSIN-II AND ANGIOTENSIN-II-(4-8)-PENTAPEPTIDE IN RATS [J].
BRASZKO, JJ ;
WLASIENKO, J ;
KUPRYSZEWSKI, G ;
WITCZUK, B ;
WISNIEWSKI, K .
PHYSIOLOGY & BEHAVIOR, 1988, 44 (03) :327-332
[6]   GFAP PROMOTER DIRECTS ASTROCYTE-SPECIFIC EXPRESSION IN TRANSGENIC MICE [J].
BRENNER, M ;
KISSEBERTH, WC ;
SU, Y ;
BESNARD, F ;
MESSING, A .
JOURNAL OF NEUROSCIENCE, 1994, 14 (03) :1030-1037
[7]   Responses to angiotensin peptides are mediated by AT1 receptors in the rat [J].
Champion, HC ;
Czapla, MA ;
Kadowitz, PJ .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 274 (01) :E115-E123
[8]   Comparative effects of angiotensin IV and two hemorphins on angiotensin-converting enzyme activity [J].
Fruitier-Arnaudin, I ;
Cohen, M ;
Bordenave, S ;
Sannier, F ;
Piot, JM .
PEPTIDES, 2002, 23 (08) :1465-1470
[9]   ANGIOTENSIN SYNTHESIS IN THE BRAIN AND INCREASED TURNOVER IN HYPERTENSIVE RATS [J].
GANTEN, D ;
HERMANN, K ;
BAYER, C ;
UNGER, T ;
LANG, RE .
SCIENCE, 1983, 221 (4613) :869-871
[10]   Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats [J].
Gohlke, P ;
Kox, T ;
Jürgensen, T ;
von Kügelgen, S ;
Rascher, W ;
Unger, T ;
Culman, J .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 (06) :477-483